Article Summary Line: Emerging *Plasmodium vivax* infections detected in 10% of febrile malaria patients and 5% of asymptomatic individuals in Duffy-negative populations in Cameroon challenge conventional malaria resistance paradigms, highlighting the need for enhanced surveillance and revised control strategies in Africa.

Running Title: Epidemiology of *vivax* malaria in Central Africa

Keywords: Malaria; *Plasmodium vivax*; *Plasmodium falciparum,* Duffy binding protein*, PvDBP1,* Cameroon

Conventional Malaria Diagnostics Vastly Undermine *Plasmodium vivax* Infections in Predominantly Duffy-Negative Africa.

Authors: Cheikh Cambel Dieng*, Rene Teh Ning, Canelle Longo Kipayko, Regan Schroeder, Nontokozo Mdluli-Berndt, Bate Ayukenchengamba, Sona Doris, Zidedine Nematchoua, Irene Sumbele Ngole Ule, Helen Kuokuo Kimbi, Eugenia Lo

Affiliations:

Drexel University College of Medicine, Philadelphia, Pennsylvania, USA (C. Dieng, C. Kipayko, R. Schroeder, N. Mdluli-Berndt, E. Lo)

University of Buea, Buea, Cameroon (R.Teh Ning, B. Ayukenchengamba, S. Doris, Z. Nematchoua, I. Sumbele Ngole Ule, H. Kuokuo Kimbi)

University of Bamenda, Bamenda, Bambili, Cameroon (H. Kuokuo Kimbi)

Abstract

Malaria remains a major public health concern in sub-Saharan Africa, and *P. vivax* is emerging in regions with predominantly Duffy-negative populations. This study investigated *P. vivax* prevalence and genetic diversity across three ecological zones in Cameroon. *P. vivax* was detected in ~11% of febrile patients and 5.5% of asymptomatic individuals, all Duffy-negative. Clinical infections exhibited higher parasitemia than community cases. Standard PvLDH-based RDTs produced false-negative results, even at high parasitemia levels, whereas molecular tools like qPCR demonstrated superior sensitivity, particularly for low-density or mixed infections. Genetic analysis of *PvDBP1* identified two prevalent mutations, I379L (73%) and E225K (61%), suggesting adaptive evolution. Phylogenetic analysis clustered Cameroonian isolates with those from Botswana, distinct from Ethiopian and Sudanese strains, indicating historical migration and local adaptation. The detection of asymptomatic *P. vivax* cases highlights the potential for silent transmission, reinforcing the need for enhanced surveillance in both community and clinical settings.

Introduction

Malaria remains a significant global health challenge in sub-Saharan Africa. For decades, *Plasmodium vivax* (*Pv)* was thought to be rare in African populations that lack the Duffy blood group antigen expression(1, 2). However, recent studies report several *Pv* cases in Duffy-negative people across Africa. The endemic range of *Pv* has extended beyond the Horn of Africa and penetrated areas of very high (>95%) Duffy-negativity. In sub-Saharan Africa, malaria

43 prevalence varies significantly by region and season. For instance, in Cameroon, the highest
44 prevalence occurs in the western and northern regions that are mostly highlands(3). The western
45 region also has higher rainfall, especially in June, which contributes to increased malaria
46 transmission. While *P. falciparum* (*Pf*) is the major parasite species, *Pv* cases were previously
47 reported, some of which were non-Cameroonians who resided in Cameroon and later diagnosed
48 after returning to their home countries(4, 5). In addition, several "*Pv*-like" asymptomatic
49 infections were identified in schoolchildren on the eastern slope of Mount Cameroon in the
50 Southwest Region, and these infections were detected solely by microscopy. Two recent studies
51 also reported an infection rate of 5.6%(6) and 35%(7) of *Pv* in febrile Duffy-negative individuals
52 in Dschang, northwestern Cameroon by PCR. Nevertheless, these studies were mostly case
53 reports without characterizing the epidemiological features of *Pv*. Also, the extent of genetic
54 polymorphisms of the Duffy Binding Protein (DBP) gene, a key gene that the parasites use to
55 invade human erythrocytes via DARC(8), is unclear among *Pv* from Duffy-negative populations
56 in Central Africa. Such variations in the African *Pv* relative to other geographical isolates have
57 important implications in the adaptability and spread of *Pv* across Africa.

58 Different environmental conditions including temperature, rainfall, and elevation can
59 impact the abundance and behavior of vector mosquitoes and the parasite's development cycle.
60 Across the diverse landscape of Cameroon, environmental factors may play a crucial role in
61 shaping the epidemiological patterns of *Pv*(9). In this study, we compared the prevalence of *Pv*
62 among the northwest, southwest, and eastern regions of Cameroon in both community and
63 hospital settings. We further examined genetic polymorphisms of *Pv* from these regions and
64 compared them to other geographical isolates including those from East Africa and outside
65 Africa, with the goal to determine genetic diversity and potential evolutionary pathways of the

parasites. The epidemiological and genetic characteristics of *Pv* in African populations, particularly in Duffy-negative individuals, are essential information for guiding effective control strategies against this emerging disease across Africa.

Methods

Ethical Statement

The study protocol was approved by the Institutional Review Boards of the Universities of Buea and Bamenda (Ref No. 2024/2110-06/UB/SG/IRB/FHS). Informed consent was obtained from all participants or their legal guardians. All methods were carried out in accordance with relevant guidelines and regulations.

Study Sites and Sample Collection

A cross-sectional study was conducted across three study sites in Cameroon: Bamenda, Buea, and Bertoua. These sites were selected based on their distinct climatic and landscape features. Bamenda is situated in a highland region (1201–1400 m). Buea, located 530 meters above sea level, is a multi-ethnic semi-urban setting where malaria transmission occurs all year-round(10, 11). Bertoua, located in the Eastern region, is known for its wet equatorial climate and economic activities in timber and mining(9). A total of 1,373 samples were collected between April and August 2023, including 793 malaria-suspected patients from hospitals and health facilities, and 580 from community-based households. Among them, 408 samples were from

86 Buea, 498 from Bamenda, and 467 from Bertoua; 555 were males and 818 were females. For
87 each individual, 30–50 μL of finger-pricked blood was preserved on Whatman 3MM filter
88 papers, air-dried and stored in sealed plastic bags until DNA extraction. Thick and thin blood
89 smears were prepared for microscopy.

90

91 ***Plasmodium* Screening, Duffy Genotyping, and *PvDBP1* Sequencing**

92 *Plasmodium* species were initially determined using rapid diagnostic tests (RDTs; Bioline
93 Malaria Ag Pf/Pv manufactured by Abbott Inc) specific to *Pf* (PfHRP2) and *Pv* (PvLDH), as
94 well as microscopy. Molecular assays were conducted for further diagnosis. Parasitic DNA was
95 extracted from dried blood spots using a modified Chelex®-saponin method(12, 13) . PCR
96 amplification targeting the 18S rRNA gene was performed with quantitative PCR(14) to
97 differentiate between mono-*Pv* and mixed *Pv*-*Pf* infections. Parasitemia was quantified using the
98 SYBR Green detection method, following established protocols using *Pv*-specific primers for
99 18S rRNA gene amplification (Supplementary File 1)(13). Each run included positive controls
100 from *Pv* Pakchong (MRA-342G) and Nicaragua (MRA-340G) isolates, along with negative
101 controls. A standard curve was generated based on a ten-fold serial dilution of a *Pv* control
102 plasmid to assess amplification efficiency (E). Specificity of the amplification was verified by
103 melting curve analysis. For each sample, the mean cycle threshold (Ct) value and standard error
104 were calculated from three independent runs. Parasitemia was determined using the equation:
105 $2^{E \times (40-Ct_{sample})}$.

106 To further confirm *Pv* infection, we amplified the *PvDBP1* gene region II using *Pv*-
107 specific primers following the published protocol(15). PCR products were purified before Sanger
108 sequencing. To identify the host Duffy blood group, we employed qPCR-based TaqMan assay to
109 examine the point mutation (c.1–67T>C; rs2814778) of the *DARC* gene(16) . A no-template
110 control was used in each assay. The *Fy* genotypes were determined by the allelic discrimination
111 plot based on the fluorescent signal emitted from the allele-specific probes. A 1,100-bp fragment
112 of the *DARC* gene was further amplified using published primers(17) .

113

114 **Data analysis**

115 To assess factors associated with mono-*Pv* and mixed *Pv*-*Pf* infections, odds ratios (OR)
116 and 95% confidence intervals (CI) were calculated for various demographic, clinical, and
117 epidemiological variables. The analysis included gender (male vs. female), age (<5 years, 5–15
118 years, and >15 years), and collection origin (community vs. hospital-based) to identify potential
119 risk factors for infection. Symptom-based associations were analyzed to evaluate whether
120 clinical presentation differed between infections caused by mono-*Pv* or mixed infections. The
121 odds ratio was used to estimate the relative risk of infection in different groups using MedCalc
122 statistical software.

123 *PvDBP1* sequences were first aligned using MUSCLE alignment tool to the P01
124 reference strain in Geneious vX.1. The prevalence of observed codon mutations was examined
125 among the Cameroonian *Pv* and compared with other isolates in Thailand and China (Asia),
126 Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa) that

represent geographically and epidemiologically diverse regions (Figure 4B). Phylogenetic trees were then constructed using Maximum Likelihood (ML) method in RAxML. The ML tree was generated with 1,000 bootstrap replicates for statistical support. The General Time Reversible (GTR) model with gamma distribution was used to account for rate heterogeneity among sites. The resulting tree was imported into FigTree v1.4.4 for visualization. Sequences are available on GenBank submission number 2920113.

Results

Prevalence of *Pv* Infections among Duffy-Negatives

The prevalence of mono-*Pv* and mixed *Pv*-*Pf* infections showed significant variation across the study sites (Figure 1).



Figure 1. Study sites across Cameroon (Bamenda, Buea, and Bertoua) by hospital and community-based collection and infection type including mono-*P. vivax*, mono-*P. falciparum*, mixed *P. vivax* and *P. falciparum*, and negative samples. The prevalence of mono-*P. vivax* and mixed *P. vivax*-*P. falciparum* infections showed significant variation across the study sites.

Among 793 hospital samples, the overall prevalence of mono-*Pv* was 11% (*n*=86), mono-*Pf* was 24.5% (*n*=192), and mixed infections was 13.5% (*n*=106; Figure 2A and Table 1). All *Pv* infections were Duffy-negative (CC) based on TaqMan genotyping assays. The highest prevalence of mono-*Pv* and mixed infections was observed in females over 15 years old in Bamenda (6% and 3.8%, respectively).

Table 1. Prevalence of Mono-*Plasmodium vivax*, Mono-*Plasmodium falciparum*, and mixed infections across different sex and age groups in Bamenda, Bertoua and Buea. This table summarizes the infection prevalence of Mono-*Plasmodium vivax* (Mono-Pv), Mono-*Plasmodium falciparum* (Mono-Pf), and Mixed Infections across three sites in Cameroon (Bamenda, Bertoua, and Buea). Data are stratified by sex and age groups (>15 years, <5 years, 5-15 years). For each site, the total number of cases and the percentage distribution of infections are provided. Chi-square tests were conducted to assess the association between infection type (Mono-Pv, Mono-Pf, Mixed) and demographic variables (age group, sex). Significant differences were observed in infection prevalence among different age groups, with higher mixed infection rates observed in females, especially children under 5, indicating a greater vulnerability to mixed infections (p-value < 0.05). Specifically, the highest prevalence of mixed infections was observed in Bamenda (36.54%), followed by Bertoua (34.26%) and Buea (29.20%).

Origin	Site	Sex	Age	Mono-*P.v*	Mono-*P.f*	Mixed Infection	*P.v*, *P.f* negative	Total
Hospital	Bamenda	Female	>15	6.0% (30)	3.2% (16)	3.8% (19)	27.3% (136)	40.4% (201)
			<5	1.4% (7)	4.4% (22)	3.8% (19)	9.8% (49)	19.5% (97)
			5-15	0.4% (2)	1.0% (5)	0	1.0% (5)	2.4% (12)
		Male	>15	1.2% (6)	1.2% (6)	0.6% (3)	8.6% (43)	11.7% (58)
			<5	1.6% (8)	3.4% (17)	2.4% (12)	16.1% (80)	23.5% (117)
			5-15	0.2% (1)	0	0.2% (1)	2.2% (11)	2.6% (13)
	Buea	Female	>15	5.6% (16)	18.2% (52)	6.7% (19)	15.1% (43)	45.6% (130)

			<5	0.7% (2)	5.6% (16)	1.1% (3)	2.8% (8)	6.7% (29)
			5-15	0.4% (1)	2.8% (8)	2.5% (7)	2.8% (8)	8.5% (24)
			>15	2.8% (8)	7.7% (22)	4.2% (12)	4.2% (12)	18.9% (54)
		Male	**<5**	1.1% (3)	5.6% (16)	1.8% (5)	2.8% (8)	11.2% (32)
			5-15	0.7% (2)	4.2% (12)	2.1% (6)	2.1% (6)	9.1% (26)
	Total (%)			10.9% (86)	24.5% (192)	13.5% (106)	52.2% (409)	100% (793)
			>15	0.6% (3)	7.5% (35)	1.9% (9)	11.3% (53)	21.4% (100)
		Female	**<5**	0.2% (1)	5.1% (24)	0.2% (2)	6.4% (30)	12.2% (57)
			5-15	0.9% (4)	11.3% (53)	0.21% (6)	7.9% (37)	21.4% (100)
	Bertoua							
			>15	0.2% (1)	3.4% (16)	0.6% (3)	4.3% (20)	8.6% (40)
		Male	**<5**	0.4% (2)	7.1% (33)	0.9% (4)	5.1% (24)	13.5% (63)
			5-15	0.21% (6)	9.9% (46)	1.7% (8)	10.1% (47)	22.9% (107)
			>15	6.2% (7)	8.8% (10)	6.2% (7)	38.9% (44)	60.2% (68)
Community		**Female**	**<5**	0	0	0	0	0
			5-15	0	0	0	0	0
	Buea							
			>15	6.2% (7)	10.6% (12)	2.7% (3)	19.5% (22)	38.9% (44)
		Male	**<5**	0.9% (1)	0	0	0	0.9% (1)
			5-15	0	0	0	0	0
	Total (%)			5.5% (32)	39.5% (229)	7.2% (42)	47.8% (277)	100% (580)

Among 580 community samples, the overall prevalence of mono-*Pv* was 5.52% (*n*=32), mono-*Pf* was 39.48% (*n*=229), and mixed infections was 7.24% (*n*=42; Figure 2A and Table 1). There were no significant differences in *Pv* infection rates between females (8.9%) and males (8.1%, OR=1.11, *p*=0.597). Similarly, mixed infections were found in 10.3% of males and 11.1% of females, with no significant difference between gender (OR=1.09, *p*=0.617). No significant difference was observed in parasitemia between mono-*Pv* and mixed *Pv*-*Pf* infections (Figure 2B), between females and males, as well as among age groups (Appendix Figure 1; Appendix Figure 2).



Figure 2. Comparison of *P. vivax* and *P. falciparum* Infections Across Hospital and Community Settings and Parasitemia Levels in Mono and Mixed Infections. (**A**) Panel shows the number of cases for *P. vivax* (*P.*v), and mixed *P. vivax* and *P.* falciparum (*P.*v & *P.*f) infections across hospital (orange bars) and community (olive green bars) settings. Among the hospital samples, 10% (86) were positive for *P. vivax* while 52.3% (409) samples showed mixed

infections, with both *P. vivax* and *P. falciparum* present. In community samples, 5.5% (32) were positive for *P.* vivax and 747.8% (277) samples showed mixed infections. (**B**) Comparison of *P. vivax* parasitemia by qPCR levels between *P.vivax* mono-infections and mixed *P. vivax* infections. No significant difference in parasitemia levels was observed between the two groups, indicating similar parasite burdens in both mono and mixed infections.

Of 119 18S-based qPCR *Pv*-positive samples, 112 (94%) were confirmed by *PvDBP*1-based PCR. However, all qPCR-positive samples were negative by microscopy (Table 2), and only 15 of them (12.6%) were positive by RDTs. These RDT-positive samples showed relatively low Ct values (i.e., high parasite DNA copies) by qPCR (Table 2). While the average parasitemia was higher in the clinical than community *Pv* infections ($p<0.001$; Figure 3), several community-based (asymptomatic at the time of collection) infections were shown with relatively high parasitemia. Specifically, 13% of community samples was within the high parasitemia range (i.e., >1,000 parasites/µL), compared to 21% of hospital cases.

Table 2. Detection of *Plasmodium vivax* Infections across Hospital- and Community-Based Samples. This table shows the *P. vivax* detection using 18S-qPCR, *PvDBP1*-targeted PCR (DBP-PCR), microscopy, and rapid diagnostic tests (RDTs) in hospital-based (N = 793) and community-based (N = 580) samples. Most infections, particularly those with higher Ct values (indicative of lower parasite densities), were undetectable by microscopy and RDT. All qPCR-positive *P. vivax* samples were from Duffy negative individuals.

Hospital-based samples (total *N*= 793)

Ct range by qPCR	18S-qPCR	DBP-PCR+	Microscopic+	RDT+
<20	0	0	0	0
20 - <25	5	5	0	5
25 - <30	17	17	0	7

30 - <35	20	18	0	0
>35 - <38	45	43	0	0
Community-based samples (total *N*= 580)				
<20	3	3	0	3
20 - <25	3	2	0	0
25 - <30	1	1	0	0
30 - <35	4	4	0	0
>35 - <38	21	19	0	0



Figure 3. Comparative Analysis of Parasitemia Levels by Sample Origin in *P. vivax* Infections. Compares parasitemia levels between hospital and community samples, showing significantly higher parasitemia in hospital samples.

Association Between Age, Infection Type, and Symptoms

Age-stratified analysis revealed significant trends in malaria prevalence. Individuals aged 5–15 years had a significantly lower risk of *Pv* infection compared to children under 5 years (OR=0.67, p=0.01). It is not surprising that *Pv* was more common in hospital-based participants (10.8%) than those from the community (5.5%), though this difference was not statistically significant (OR=1.16, p=0.162). Likewise, mixed infections were also more common in hospital (13.3%) than community samples (7.2%), with a significant two-fold increased risk (OR=2.04, p<0.001). Mono-*Pv* infections were not significantly associated with any reported symptoms (fever, nausea, diarrhea, difficulty breathing, muscle pain, or chills); and headache was the only symptom significantly associated with *Pf* infections (OR=3.33, p=0.004; Table 3).

Table 3. Demographic, Geographic, and Symptom-Based Risk Factors Associated with *Plasmodium vivax*, *Plasmodium falciparum*, and Mixed Infections. This table presents the distribution of malaria infections across various demographic, geographic, and clinical symptom categories. Significant associations (**$p < 0.05$**) were observed for several risk factors. Individuals aged **5–15 years** had a significantly **lower risk of *P. vivax* infection**, while those **older than 15 years** had a **higher risk of *P. falciparum* infection**. Hospital-based samples had a **higher prevalence of mixed infections** and a **lower prevalence of *P. falciparum*** compared to community-based cases. Among clinical symptoms, **headache was significantly associated with *P. falciparum* infection**, whereas no other symptoms showed strong associations. These findings suggest that age, geographic origin, and specific clinical presentations contribute to malaria transmission dynamics and severity.

Variables	Number of Samples	Total Infections	Odds ratio [95% CI]	*P. vivax*	Odds ratio [95% CI]	*P. falciparum*	Odds ratio [95% CI]	Mixed Infections	Odds ratio [95% CI]
Overall									
	1373	50.0% [687]		8.6% [118]		30.7% [421]		10.8% [148]	
Sex									
Female	59.5% [818]	58.9% [405]	1	8.9% [73]	1	29.5% [241]	1	11.1% [91]	1
Male	40.4% [555]	41.0% [282]	0.95 [0.77 to 1.18] **P= 0.636**	8.1% [45]	1.11 [0.75 to 1.64] **P= 0.597**	32.4% [180]	0.87 [0.69 to 1.09] **P= 0.242**	10.3% [57]	1.09 [0.77 to 1.55] **P= 0.617**
Age									
<5	28.8% [396]	28.5% [196]	1	5.9% [23]	1	33.2% [128]	1	11.7% [45]	1
5-15	20.5% [282]	24.6% [168]	0.67 [0.49 to 0.91] **P= 0.01***	5.7% [16]	1.03 [0.53 to 1.98] **P= 0.941**	43.9% [124]	0.61 [0.44 to 0.83] **P= 0.002****	9.9% [28]	1.16 [0.71 to 1.91] **P= 0.553**
>15	50.6% [695]	46.9% [322]	1.14 [0.89 to 1.53] **P= 0.314**	11.2% [78]	0.49 [0.30 to 0.79] **P= 0.004****	24.3% [169]	1.49 [1.13 to 1.95] **P= 0.004****	10.8% [75]	1.06 [0.72 to 1.57] **P= 0.772**
Origin									
Community	42.2% [580]	52.2% [303]	1	5.5% [32]	1	39.5% [229]	1	7.2% [42]	1
Hospital	57.7% [793]	48.4% [384]	1.16 [0.94 to 1.44] **P= 0.162**	10.8% [86]	0.48 [0.32 to 0.73] **P= 0.001****	24.2% [192]	2.04 [1.62 to 2.58] **P < 0.0001****	13.3% [106]	0.51 [0.35 to 0.74] **P= 0.0004****

Symptoms									
Fever	0.3% [4]	0.29% [2]	1	25.0% [1]	1	25.0% [1]	1	0	1
Chills	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P = 0.378**
Abdominal Pain	0.4% [5]	0.29% [2]	1.50 [0.11 to 21.31] **P = 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0	4.71 [0.15 to 151.49] **P= 0.381**	40.0% [2]	0.15 [0.01to 4.39] **P= 0.275**
Headache*(data missing)	0.8% [11]	0.73% [5]	1.20 [0.12 to 11.87] **P= 0.876**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	9.1% [1]	3.33 [0.16 to 70.91] **P= 0.440**	27.3% [3]	0.27 [0.01 to 6.46] **P= 0.419**
Nausea	0.1% [1]	0	3.00 [0.08 to 115.35] **P= 0.555**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	1.29 [0.03 to 53.52] **P= 0.895**	0	0.33 [0.00 to 25.41] **P= 0.619**
Diarrhea	0.2% [2]	0	5.00 [0.15 to 166.59] **P= 0.368**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	2.14 [0.06 to 77.54] **P= 0.677**	0	0.56 [0.01 to 37.56] **P= 0.785**
Difficulty Breathing	0	0	1.00 [0.01 to 73.27] **P= 1.000**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.43 [0.01 to 33.59] **P= 0.703**	0	0.11 [0.00 to 14.76] **P= 0.378**
Muscle Pain	0.4% [5]	0.44% [3]	0.67 [0.05 to 9.47] **P= 0.765**	0	4.71 [0.15 to 151.49] **P= 0.381**	0.20% [1]	1.33 [0.06 to 31.12] **P= 0.858**	40.0% [2]	0.16 [0.00 to 4.39] **P= 0.275**
Fatigue	0.7% [9]	0.44% [3]	2.00 [0.18 to 22.05] **P= 0.571**	22.2% [2]	0.67 [0.05 to 9.47] **P= 0.765**	0	8.14 [0.26 to 250.74] **P= 0.230**	11.1% [1]	0.63 [0.02 to 18.83] **P= 0.789**

230

231 **Genetic polymorphisms of *PvDBP1* and Phylogenic Relatedness**

232 A total of eight mutations were identified in the *PvDBP1* region II (amino acid 291-460)
233 among 75 *Pv* isolates from Cameroon, of which two mutations showed exceptionally high
234 frequency in the Duffy-negative populations. They included I379L observed in 74.1% and
235 E225K in 53.7% of the samples (Figure 4A). Other less frequent mutations included N372K
236 (27.8%), G339D (22.2%), W442C (11.1%), K234E (47.1%), K326E (7.4%), and G417V (5.6%).
237 The four variants detected in the Cameroon *Pv* including K326E, G339D, N372K, and I379L
238 were shared with the Thai isolates, though I379L (30%) and G339D (19%) were observed at
239 considerably lower frequencies in Thailand (Figure 4B). Only two mutations K326E and N372K
240 were shared between the Cameroonian and Botswana isolates. The Chinese *Pv* was most
241 polymorphic with 13 variants in the binding region. Among them, L333F, N375D, S398T, and
242 T404R were unique and not observed elsewhere. The remaining nine variants were overlapped
243 with the Sudanese, Ethiopian, and Brazilian isolates. However, none of these variants were
244 detected in the Cameroonian and Botswana *Pv*. Both the Brazilian and Sudanese/Ethiopian
245 isolates had mutations K371E, E385K, and L424I, but only N417K was overlapped with the
246 Cameroonian *Pv* (Figure 4B).

247



(B)

Country	Region	Number of Isolates	R308S	K326E	L333F	G339D	K371E	N372K	N375D	I379L	D384G	E385K	K386N/Q	R390H	S398T	T404R	N417K	L424I	W437R	W442C
Cameroon	Central Africa	75		✓		✓		✓		✓							✓			✓
Botswana	Southern Africa	12		✓				✓												
Ethiopia	East Africa	78	✓				✓					✓		✓				✓		
Sudan	East Africa	60	✓				✓				✓	✓	✓	✓			✓	✓	✓	
Brazil	South America	15					✓					✓	✓				✓	✓		
China	Southeast Asia	18	✓		✓		✓		✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	
Thailand	Southeast Asia	10		✓		✓		✓		✓										

Figure 4. **Distribution of DBP Gene Mutations in *P. vivax* Isolates from Cameroon and Global Comparisons:** (**A**) The bar chart illustrates the frequency of *Plasmodium vivax* Duffy Binding Protein (DBP) gene mutations in isolates from Cameroon. The mutations E225K, K234E, K326E, G339D, N372K, I379L, G417V, and W442C were observed with varying prevalence, with I379L showing the highest frequency. Mutations marked with an asterisk (*)—K326E, G339D, N372K, and I379L—are also observed in Thailand. (**B**) Comparison of *PvDBP1* Region II mutations observed in *P. vivax* isolates from Cameroon with those reported in geographically and epidemiologically diverse regions, including Thailand and China (Asia), Brazil (South America), Sudan and Ethiopia (East Africa), and Botswana (Southern Africa). Cameroon shared four mutations (K326E, G339D, N372K, and I379L) with Thailand, though the frequencies of I379L and G339D were lower in Thai isolates. K326E and I379L were also found in Botswana. Brazilian and Sudanese/Ethiopian isolates exhibited a broader mutation profile, including several variants not found in Cameroon. Chinese isolates displayed unique mutations such as L333F, S398T, and T404R.

Phylogenetic analyses indicated distinct genetic clustering of *Pv* isolates from various geographic regions, highlighting both global diversity and regional adaptation. *Pv* populations

266 from Central-South Africa, South America, Asia, and East Africa were found in separate clusters
267 (Figure 5A), of which the African and Asian *Pv* were closely related. *Pv* from South America
268 formed a distinct clade separated from the other regions. When *Pv* from Africa were analyzed
269 alone (Figure 5B), most of the isolates from Cameroon (in red) form a distinct cluster, sister to
270 those from Botswana (light blue). Two other main clades were observed—one contained mostly
271 Ethiopian (purple) and Ugandan (orange) isolates, and another contained the Ethiopian and
272 Sudanese (green) isolates, indicating substantial diversity among the African *Pv*.

273



274
275 **Figure 5. Global and Regional Phylogenetic Relationships of *Plasmodium vivax* Isolates.**
276 This figure illustrates the phylogenetic relationships of *Plasmodium vivax* isolates from different
277 geographical regions using whole genome sequence data: (**A**) Displays a circular phylogenetic
278 tree that segregates *P. vivax* populations into major global regions, including Central-South
279 Africa, South America, Asia, and East Africa; (**B**) Presents a radial phylogenetic tree, with color-
280 coded branches corresponding to isolates from Cameroon (red), Botswana (light blue), Uganda
281 (orange), Ethiopia (purple), Sudan (green), and reference genomes (yellow). Both trees

demonstrate the genetic diversity and evolutionary divergence of *P. vivax* across different geographical populations, with significant clustering observed among isolates from specific regions. The phylogenetic structure highlights potential gene flow and regional adaptation patterns, particularly in East African populations. These insights are crucial for understanding the evolutionary history and transmission dynamics of *P. vivax* on both global and regional scales.

Discussion

Molecular assays by 18S rRNA and *PvDBP1* indicated a large number of *Pv* cases in different parts of Cameroon. These findings challenge the longstanding dogma that Duffy-negative individuals are resistant to the parasite but instead suggesting that *Pv* could be well adapted and circulating broadly in predominantly Duffy-negative Central Africa(7, 16, 18). Geographical and environmental factors play a crucial role in shaping *Pv* transmission dynamics in Africa(19). The southwest region of Cameroon, such as Buea, situated at a higher altitude on the slope of Mount Cameroon, presents favorable conditions for *Pv* development due to its relatively lower temperatures. Unlike *Pf*, which requires warmer temperatures (18°C and above) for its development in mosquito vectors, *Pv* can develop at temperatures as low as 16°C to 18°C, albeit at a slower rate(20). This unique thermal tolerance may allow *Pv* to thrive in cooler environments. High rainfall and frequent flooding in Buea and Bamenda likely contribute to higher malaria transmission compared to Bertoua(21). Recent evidence suggests that malaria is expanding its endemic range to higher altitudes, including regions such as the Ethiopian highlands(18), Kenya(19), and Colombia(21). In Ethiopia, *Pv* has spread into previously malaria-free highland areas with a mono-*Pv* infection rate of ~8%, similar to our findings. Due to socio-political unrest and large-scale migration in the English-speaking regions of Cameroon since 2016, *Pv* may have readily spread to different parts of Cameroon or beyond. Individuals aged 5–

306 15 years had a significantly lower risk of *Pv* than children under 5 years, suggesting partial
307 immunity or reduced exposure(22). The potential spread and adaptation of *Pv* emphasizes the
308 need to consider geographical/environmental heterogeneity when developing malaria control and
309 intervention strategies.

310 It is not surprising that hospital-based samples exhibit higher parasitemia. However,
311 several asymptomatic infections from the community were shown with relatively high
312 parasitemia that may contribute to onward transmission. In Ethiopia, *Pv* in Duffy-negative
313 individuals was reported in both asymptomatic volunteers from communities and febrile
314 patients(23, 24), and was shown with gametocytes(25). The use of microscopy and RDT
315 diagnostics, though convenient, could vastly misidentified or missed low-density *Pv* infections.
316 In this study, some individuals classified as microscopy-negative showed moderate to high
317 parasitemia by qPCR, raising concerns about the diagnostic sensitivity of microscopy and
318 PvLDH-based RDTs, especially in Duffy-negative individuals. Similar microscopy results have
319 been reported in Indonesia(26), where microscopy detected only 5 mixed *Pv*-*Pf* cases, while
320 nested PCR detected 346 cases across various clinical categories, including asymptomatic
321 individuals and those treated with antimalarials(26). Our findings indicated that PvLDH-based
322 RDTs may contribute to false-negative results, even in cases of high parasitemia. This could be
323 attributed to defective or degraded test kits, lot variability, or antigenic variation that affects the
324 detection capability of PvLDH in majority Duffy-negative Africans. Molecular tools like qPCR
325 offer superior sensitivity and specificity, particularly in detecting low-density or mixed *Pv*
326 infections, ensuring both symptomatic and asymptomatic carriers are identified and monitored
327 effectively.

328 The *PvDBP1* gene encodes a critical ligand that facilitates *Pv* invasion of human
329 erythrocytes by binding to the Duffy antigen receptor, making it a key molecular marker for both
330 species confirmation and evolutionary analysis. While previous studies in Cameroon have
331 documented the presence of *Pv*, this is the first study to utilize *PvDBP1* not only to validate *Pv*
332 infections in Duffy-negative individuals, but also to examine genetic variations and phylogenetic
333 relationships of the Cameroonian *Pv* with global populations**.** In the Cameroonian *Pv*, mutations
334 I379L and E225K occurred at high frequencies. These and several other identified mutations,
335 including K326E, G339D, and N372K overlapped with *Pv* populations from Southeast Asia(27).
336 Mutations I379L and G339D occurred at substantially higher frequencies in our dataset than
337 other geographical isolates, suggesting regional adaptation or selective pressures in Central
338 African parasite populations. Future functional assays would clarify their role in parasite
339 invasion and virulence.

340 Previous studies indicated striking similarity of the *Pv* genome between Asian and East
341 African parasite populations with high identity-by-descent(20). Our recent studies found no clear
342 genetic differentiation in *Pv* between Duffy-negatives and Duffy-positives, supporting the notion
343 of shared ancestry and gene flow between the two populations(16, 28). The present findings
344 further highlighted the genetic relatedness of the Cameroonian and Botswana *Pv* and that both
345 being distinct from the East African isolates. Such differentiation may reflect local adaptation of
346 the parasites to regional ecological and host conditions. Ecological variation, particularly in
347 mosquito vector dynamics, likely plays a significant role in shaping *Pv* population structure and
348 transmission. For example, *Plasmodium* parasites have been shown with great compatibility with
349 sympatric mosquito species(29). In Cameroon and Benin, *Anopheles coluzzii* was identified as a
350 competent vector for *Pv*(30), suggesting its potential significance in sustaining transmission in

West/Central Africa(31). By contrast, in East Africa, *An. arabiensis* and *An. funestus* are primary vectors for malaria transmission. While *An. arabiensis* is more commonly associated with *Pf*, there is evidence suggesting its potential role in transmitting *Pv* (32, 33)(34). Adaptation to different mosquito vector populations may drive genetic distinctiveness between the Central and East African *Pv*.

Apart from vector-parasite co-evolution, host genetic factors may also play a role in shaping parasite population structure. Evidence of a severe population bottleneck followed by rapid expansion in human *Pv*, along with the pseudogenization of genes such as *RBP2d*, *RBP2e*, and *RBP3*, which remain intact in ape *Pv*, supports the notion of host-specific adaptation in parasite populations(35). The distinct *Pv* population structures observed between East and Central/Southern Africa may reflect differences in historical human migration and host reservoirs. East Africa, where Duffy-positive individuals account for two-third of the general populations and that *Pv* has been circulating for a long time in the region, likely represents a larger, more ancestral parasite gene pool; whereas Central and Southern Africa may represent a portion of *Pv* parasites recently introduced from East Africa that shaped by bottlenecks and the predominance of Duffy-negative hosts(35, 36). The observed genetic relatedness between Cameroonian and Botswanan isolates suggests possible recent gene flow. The Bantu expansion is the most significant and well-studied migration event between Central and Southern Africa, where Bantu-speaking people migrated from West-Central Africa, eventually settling in much of the southern half of the continent and interacting with indigenous groups like the Khoisan, around 3,000 to 5,000 years ago(37, 38). This migration event could have shaped the parasite population structure.

373 This study has a few limitations. First, samples and related metadata were collected at a
374 single timepoint and thus restricts our ability to assess *Pv* transmission over time. Also, the
375 genetic analysis based on *PvDBP1* alone does not reflect evolutionary changes at the genome
376 level for *Pv* in Duffy-negative individuals. The geographic representation of African *Pv* isolates,
377 particularly samples from West Africa, is limited in the phylogenetic analysis. The apparent
378 genetic distinctiveness of Central African isolates may change with broader sampling across the
379 continent. Our ongoing investigations use a genome-based approach together with spatial
380 analyses to determine source-sink dynamics of *Pv* infections, with the goal to unravel the origin
381 and adaptation of *Pv* in Africa.

382 To conclude, the detection of several *Pv* cases in asymptomatic individuals underscores
383 its potential for silent transmission, emphasizing the need for enhanced surveillance in both
384 community and clinical settings. PvLDH-based RDTs may contribute to false-negative
385 diagnostic results, even in cases of high parasitemia. Molecular tools like qPCR offer superior
386 sensitivity and specificity, particularly in detecting low-density or mixed *Pv* in Duffy-negative
387 individuals. Our present findings call for tailored malaria control strategies that consider both
388 geographical/environmental heterogeneity and the unique features of *Pv* in Duffy-negative
389 populations.

390

391 **Acknowledgments**

392 We extend our sincere gratitude to Jordan Bennett for her valuable contributions in this
393 study. We also acknowledge the dedicated team in Cameroon for their invaluable efforts in

sample collection, processing, and logistical support. Their commitment and diligence were essential to the successful completion of this study. Additionally, we thank our collaborators and supporting institutions for their contributions and insights, which have significantly enriched this research.

Funding

This research was supported by an institutional grant from Drexel University. The funding body had no role in the study design, data collection, analysis, manuscript preparation, or decision to publish.

Author Bio

Dynamic and results-driven postdoctoral fellow at Drexel University College of Medicine with extensive experience in global health research, molecular diagnostics, and health technology implementation. Demonstrated expertise in malaria genomics, vaccine efficacy evaluation, and digital health innovation. Proven track record in managing cross-functional teams, leading NIH-funded studies, and collaborating with international stakeholders to drive impactful health interventions.

412 ***Address for correspondence**: Cheikh Cambel Dieng, Department of Microbiology and
413 Immunology, College of Medicine, Drexel University, Philadelphia 19129, Pennsylvania, USA;
414 email: cd3424@drexel.edu;
415

416

417 **References**

418 1. Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB, Amoah LE, Afrane YA, et al.
419 Contrasting Asymptomatic and Drug Resistance Gene Prevalence of Plasmodium falciparum in
420 Ghana: Implications on Seasonal Malaria Chemoprevention. Genes (Basel). 2019 Jul 16;10(7).
421 2. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, et al.
422 Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to
423 Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8.
424 3. Ngum NH, Fakeh NB, Lem AE, Mahamat O. Prevalence of malaria and associated
425 clinical manifestations and myeloperoxidase amongst populations living in different altitudes of
426 Mezam division, North West Region, Cameroon. Malar J. 2023 Jan 19;22(1):20.
427 4. Gautret P, Legros F, Koulmann P, Rodier M, Jacquemin J-L. Imported Plasmodium
428 vivax malaria in France: geographical origin and report of an atypical case acquired in Central or
429 Western Africa. Acta tropica. 2001;78(2):177-81.
430 5. Mangoni ED, Severini C, Menegon M, Romi R, Ruggiero G, Majori G. Case report: An
431 unusual late relapse of Plasmodium vivax malaria. American Journal of Tropical Medicine and
432 Hygiene. 2003;68(2):159-60.

433 6. Russo G, Faggioni G, Paganotti GM, Djeunang Dongho GB, Pomponi A, De Santis R, et
434 al. Molecular evidence of Plasmodium vivax infection in Duffy negative symptomatic
435 individuals from Dschang, West Cameroon. Malar J. 2017 Feb 14;16(1):74.
436 7. Djeunang Dongho GB, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M,
437 Efeutmecheh Sangong R, et al. Plasmodium vivax Infections Detected in a Large Number of
438 Febrile Duffy-Negative Africans in Dschang, Cameroon. Am J Trop Med Hyg. 2021 Jan
439 12;104(3):987-92.
440 8. Ntumngia FB, McHenry AM, Barnwell JW, Cole-Tobian J, King CL, Adams JH. Genetic
441 variation among Plasmodium vivax isolates adapted to non-human primates and the implication
442 for vaccine development. Am J Trop Med Hyg. 2009 Feb;80(2):218-27.
443 9. Seraphin EH, Lagarde BJ, Richard P, Jules N, Farrick NO. Diversity, structure and health
444 of a cocoa based agroforest system in the Humid dense forest, East Cameroon. International
445 Journal of Biodiversity andConservation. 2021:165.
446 10. Akenji T, Ntonifor N, Kimbi H, Abongwa E, Ching J, Anong D, et al. The epidemiology
447 of malaria in Bolifamba, a rural setting of Mount Cameroon: Seasonal variations in
448 parasitological indices of transmission [MIM-TA-141660]. ACTA TROPICA; 2005:
449 ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS; 2005. p.
450 S295-S6.
451 11. Fru-Cho J, Bumah VV, Safeukui I, Nkuo-Akenji T, Titanji VP, Haldar K. Molecular
452 typing reveals substantial Plasmodium vivax infection in asymptomatic adults in a rural area of
453 Cameroon. Malar J. 2014 May 3;13:170.

454 12. Miguel RB, Coura JR, Samudio F, Suárez-Mutis MC. Evaluation of three different DNA
455 extraction methods from blood samples collected in dried filter paper in Plasmodium subpatent
456 infections from the Amazon region in Brazil. Rev Inst Med Trop Sao Paulo. 2013;55(3).
457 13. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K, et al. Molecular
458 epidemiology of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive
459 and Duffy-negative populations in Ethiopia. Malar J. 2015 Feb 19;14:84.
460 14. Abagero BR, Rama R, Obeid A, Tolossa T, Legese F, Lo E, et al. Detection of Duffy
461 Blood Group Genotypes and Submicroscopic Plasmodium Infections Using Molecular
462 Diagnostic Assays in Febrile Malaria Patients. Res Sq. 2023 Dec 6.
463 15. Gunalan K, Lo E, Hostetler JB, Yewhalaw D, Mu J, Neafsey DE, et al. Role of
464 Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null Africans. Proc Natl Acad
465 Sci U S A. 2016 May 31;113(22):6271-6.
466 16. Lo E, Russo G, Pestana K, Kepple D, Abagero BR, Dongho GBD, et al. Contrasting
467 epidemiology and genetic variation of Plasmodium vivax infecting Duffy-negative individuals
468 across Africa. International Journal of Infectious Diseases. 2021;108:63-71.
469 17. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.
470 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people.
471 Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5967-71.
472 18. Ketema T, Bacha K, Getahun K, Portillo HAD, Bassat Q. Plasmodium vivax
473 epidemiology in Ethiopia 2000-2020: A systematic review and meta-analysis. PLoS Negl Trop
474 Dis. 2021 Sep;15(9):e0009781.
475 19. Shanks GD, Hay SI, Omumbo JA, Snow RW. Malaria in Kenya's western highlands.
476 Emerg Infect Dis. 2005 Sep;11(9):1425-32.

477 20. Benavente ED, Manko E, Phelan J, Campos M, Nolder D, Fernandez D, et al. Distinctive
478 genetic structure and selection patterns in Plasmodium vivax from South Asia and East Africa.
479 Nat Commun. 2021 May 26;12(1):3160.
480 21. Siraj AS, Santos-Vega M, Bouma MJ, Yadeta D, Ruiz Carrascal D, Pascual M.
481 Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. Science. 2014
482 Mar 7;343(6175):1154-8.
483 22. Wamae K, Wambua J, Nyangweso G, Mwambingu G, Osier F, Ndung'u F, et al.
484 Transmission and Age Impact the Risk of Developing Febrile Malaria in Children with
485 Asymptomatic Plasmodium falciparum Parasitemia. J Infect Dis. 2019 Feb 23;219(6):936-44.
486 23. Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.
487 Comparison of Plasmodium Vivax Infections in Duffy Negatives From Community and Health
488 Center Collections in Ethiopia. Res Sq. 2023 Oct 3.
489 24. Bradley L, Yewhalaw D, Hemming-Schroeder E, Jeang B, Lee MC, Zemene E, et al.
490 Epidemiology of Plasmodium vivax in Duffy negatives and Duffy positives from community and
491 health centre collections in Ethiopia. Malar J. 2024 Mar 14;23(1):76.
492 25. Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine
493 candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a
494 Phase I trial. NPJ Vaccines. 2018;3:48.
495 26. Deo DA, Herningtyas EH, Intansari US, Perdana TM, Murhandarwati EH, Soesatyo M.
496 Difference between Microscopic and PCR Examination Result for Malaria Diagnosis and
497 Treatment Evaluation in Sumba Barat Daya, Indonesia. Trop Med Infect Dis. 2022 Jul 29;7(8).

498 27. Tapaopong P, da Silva G, Chainarin S, Suansomjit C, Manopwisedjaroen K, Cui L, et al.
499 Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and
500 Merozoite Surface Protein-1 in northwestern Thailand. Infect Genet Evol. 2023 Sep;113:105467.
501 28. Kepple D, Hubbard A, Ali MM, Abargero BR, Lopez K, Pestana K, et al. Plasmodium
502 vivax From Duffy-Negative and Duffy-Positive Individuals Share Similar Gene Pools in East
503 Africa. J Infect Dis. 2021 Oct 28;224(8):1422-31.
504 29. Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, et al. Local
505 adaptation and vector-mediated population structure in Plasmodium vivax malaria. Mol Biol
506 Evol. 2008 Jun;25(6):1245-52.
507 30. Feufack-Donfack LB, Sarah-Matio EM, Abate LM, Bouopda Tuedom AG, Ngano
508 Bayibéki A, Maffo Ngou C, et al. Epidemiological and entomological studies of malaria
509 transmission in Tibati, Adamawa region of Cameroon 6 years following the introduction of long-
510 lasting insecticide nets. Parasit Vectors. 2021 May 8;14(1):247.
511 31. Ossè RA, Tokponnon F, Padonou GG, Glitho ME, Sidick A, Fassinou A, et al. Evidence
512 of Transmission of Plasmodium vivax 210 and Plasmodium vivax 247 by Anopheles gambiae
513 and An. coluzzii, Major Malaria Vectors in Benin/West Africa. Insects. 2023 Feb 25;14(3).
514 32. Massebo F, Balkew M, Gebre-Michael T, Lindtjørn B. Entomologic inoculation rates of
515 Anopheles arabiensis in southwestern Ethiopia. Am J Trop Med Hyg. 2013 Sep;89(3):466-73.
516 33. Eligo N, Wegayehu T, Pareyn M, Tamiru G, Lindtjørn B, Massebo F. Anopheles
517 arabiensis continues to be the primary vector of Plasmodium falciparum after decades of malaria
518 control in southwestern Ethiopia. Malar J. 2024 Jan 9;23(1):14.
519 34. Ogola EO, Odero JO, Mwangangi JM, Masiga DK, Tchouassi DP. Population genetics of
520 Anopheles funestus, the African malaria vector, Kenya. Parasit Vectors. 2019 Jan 8;12(1):15.

521 35. Loy DE, Plenderleith LJ, Sundararaman SA, Liu W, Gruszczyk J, Chen YJ, et al.
522 Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related
523 ape parasites. Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8450-e9.
524 36. Abebe A, Dieng CC, Dugassa S, Abera D, Shenkutie TT, Assefa A, et al. Genetic
525 differentiation of Plasmodium vivax duffy binding protein in Ethiopia and comparison with other
526 geographical isolates. Malar J. 2024 Feb 23;23(1):55.
527 37. Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in
528 Africa. Curr Biol. 2010 Feb 23;20(4):R166-73.
529 38. Campbell MC, Hirbo JB, Townsend JP, Tishkoff SA. The peopling of the African
530 continent and the diaspora into the new world. Curr Opin Genet Dev. 2014 Dec;29:120-32.

531

532

533

534

535

536

537

538